SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Michelle Martinot-Peignoux, Martine Lapalus, Tarik Asselah, Patrick Marcellin, HBsAg quantification: useful for monitoring natural history and treatment outcome, Liver International, 2014, 34,
  2. 2
    Emilia Hadziyannis, Stephanos J Hadziyannis, Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility, Expert Review of Gastroenterology & Hepatology, 2014, 8, 2, 185

    CrossRef

  3. 3
    Yuecheng Yu, Jinlin Hou, Masao Omata, Yue Wang, Lanjuan Li, Loss of HBsAg and antiviral treatment: from basics to clinical significance, Hepatology International, 2014, 8, 1, 39

    CrossRef

  4. 4
    Jing Lai, Chao-Shuang Lin, Lin Yang, Shu-Ru Chen, Ye-Qiong Zhang, Wei-Min Ke, Pretreatment HBsAg level and an early decrease in MELD score predict prognosis to lamivudine treatment for HBeAg-negative acute-on-chronic liver failure, Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 3, 331

    CrossRef

  5. 5
    Jing Lai, Hai-xia Sun, Yu-sheng Jie, Ka Zhang, Wei-min Ke, Serum HBsAg level and its clinical significance in lamivudine treatment for patients with HBeAg-negative acute-on-chronic liver failure, International Journal of Infectious Diseases, 2014, 22, 78

    CrossRef

  6. 6
    Jian Liang, Man Jun Jiang, Xin Deng, Xiao Xiao Zhou, Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study, Hepatitis Monthly, 2013, 13, 5

    CrossRef

  7. 7
    Michelle Martinot-Peignoux, Tarik Asselah, Patrick Marcellin, HBsAg Quantification to Predict Natural History and Treatment Outcome in Chronic Hepatitis B Patients, Clinics in Liver Disease, 2013, 17, 3, 399

    CrossRef

  8. 8
    Yasuteru Kondo, Masashi Ninomiya, Eiji Kakazu, Osamu Kimura, Tooru Shimosegawa, Hepatitis B Surface Antigen Could Contribute to the Immunopathogenesis of Hepatitis B Virus Infection, ISRN Gastroenterology, 2013, 2013, 1

    CrossRef

  9. 9
    Stéphane Chevaliez, Is HBsAg quantification ready, for prime time?, Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 6, 559

    CrossRef

  10. 10
    Stéphane Chevaliez, Christophe Hézode, Stéphane Bahrami, Marion Grare, Jean-Michel Pawlotsky, Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely, Journal of Hepatology, 2013, 58, 4, 676

    CrossRef

  11. 11
    Wai-Kay Seto, Danny Ka-Ho Wong, James Fung, Fung-Yu Huang, Ching-Lung Lai, Man-Fung Yuen, Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy, Hepatology, 2013, 58, 3
  12. 12
    Yun-hao Xun, Guo-qing Zang, Jian-chun Guo, Xiu-li Yu, Hong Liu, Jing Xiang, Jing Liu, Jun-ping Shi, Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers, Journal of Gastroenterology and Hepatology, 2013, 28, 11
  13. You have free access to this content13
    Michelle Martinot-Peignoux, Martine Lapalus, Tarik Asselah, Patrick Marcellin, The role of HBsAg quantification for monitoring natural history and treatment outcome, Liver International, 2013, 33,
  14. 14
    Massimo Fasano, Pietro Lampertico, Alfredo Marzano, Vito Di Marco, Grazia Anna Niro, Giuseppina Brancaccio, Andrea Marengo, Gaetano Scotto, Maurizia Rossana Brunetto, Giovanni Battista Gaeta, Mario Rizzetto, Gioacchino Angarano, Teresa Santantonio, HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years, Journal of Hepatology, 2012, 56, 6, 1254

    CrossRef